XML 37 R30.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting (Tables)
9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Revenue, Segment Profit and Segment Expenses The following table illustrates reported segment revenue, segment profit and significant segment expenses (in thousands):

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

NUPLAZID net revenue

 

$

177,530

 

 

$

159,186

 

 

$

505,730

 

 

$

446,518

 

DAYBUE net revenue

 

 

101,103

 

 

 

91,215

 

 

 

281,786

 

 

 

251,677

 

Total revenues

 

 

278,633

 

 

 

250,401

 

 

 

787,516

 

 

 

698,195

 

Less:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

 

8,041

 

 

 

7,357

 

 

 

25,636

 

 

 

24,861

 

License fees and royalties

 

 

13,606

 

 

 

11,500

 

 

 

37,137

 

 

 

35,177

 

Research and development expense:

 

 

 

 

 

 

 

 

 

 

 

 

External research and development

 

 

60,153

 

 

 

48,137

 

 

 

169,457

 

 

 

141,007

 

Internal costs(1)

 

 

24,676

 

 

 

17,969

 

 

 

71,588

 

 

 

55,011

 

Upfront and milestone payments

 

 

3,000

 

 

 

500

 

 

 

3,000

 

 

 

6,500

 

Total research and development expense

 

 

87,829

 

 

 

66,606

 

 

 

244,045

 

 

 

202,518

 

Selling, general and administrative

 

 

133,401

 

 

 

133,294

 

 

 

393,278

 

 

 

358,348

 

Interest income, net

 

 

(8,246

)

 

 

(6,586

)

 

 

(23,390

)

 

 

(18,451

)

Other income

 

 

(593

)

 

 

(576

)

 

 

(1,775

)

 

 

(1,248

)

Income tax (benefit) expense

 

 

(27,184

)

 

 

6,041

 

 

 

(4,847

)

 

 

14,281

 

Consolidated net income

 

$

71,779

 

 

$

32,765

 

 

$

117,432

 

 

$

82,709

 

_______________

(1)
Includes personnel expenses and costs allocated to multiple research and development programs, including benefits, information technology, facilities and inventory.